Background: HLA-matched platelets (PLTs) are widely used to transfuse patients but the effectiveness of HLA matching has not been well defined and the cost is approximately five times the cost of preparing the random-donor PLTs. The objective of this systematic review was to determine whether HLA-matched PLTs lead to a reduction in mortality; reduction in frequency or severity of hemorrhage; reduction in HLA alloimmunization, refractoriness, or PLT utilization; or improvement in PLT count increment in patients with hypoproliferative thrombocytopenia.
Study Design And Methods: We conducted a literature search of MEDLINE, Cochrane Controlled Register of Clinical Trials, EMBASE, and PubMed databases to April 2012.
Results: A total of 788 citations were reviewed and 30 reports were included in the analysis. Most studies did not include technologies currently in use for HLA typing or detection of HLA antibodies as 75% were conducted before the year 2000. None of the studies were adequately powered to detect an effect on mortality or hemorrhage. HLA-matched PLTs did not reduce alloimmunization and refractoriness rates beyond that offered by leukoreduction, and utilization was not consistently improved. HLA-matched PLTs led to better 1-hour posttransfusion count increments and percentage of PLT recovery in refractory patients; however, the effect at 24 hours was inconsistent.
Conclusion: The correlation of the PLT increment with other clinical outcomes and the effect of leukoreduction on HLA-matched PLT transfusion could not be determined. Prospective studies utilizing current technology and examining clinical outcomes are necessary to demonstrate the effectiveness of HLA-matched PLT transfusion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/trf.12175 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of storage on quality and function of acid-treated platelets with reduced HLA Class I surface expression.
Transfus Med
August 2023
Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.
Background: Refractory patients need to be provided with HLA-matched platelets (PLTs), which require time-consuming cross-matching. Treatment of PLTs with citric acid leads to denaturation of the HLA Class I complexes without significant damage to the PLTs. HLA Class I depleted PLTs could alternatively be used to HLA-matched PLTs for transfusion.
View Article and Find Full Text PDFLoss of heterozygosity leading to incorrect HLA typing for platelet-transfusion refractory patient.
Transfusion
January 2023
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Background: Management of platelet-transfusion refractory (PR) patients due to anti-HLA antibodies includes the provision of HLA-matched (HLAm) platelets (PLT) or PLTs that are negative for HLA antigens corresponding to the recipient antibodies. Obtaining HLAm PLTs is predicated on accurate HLA antigen typing of the recipient and donor. Here, we present the clinical implications of a case involving loss of heterozygosity (LOH) in a patient presented for PR workup.
View Article and Find Full Text PDFGeneration of HLA Universal Megakaryocytes and Platelets by Genetic Engineering.
Front Immunol
February 2022
Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Patelet transfusion refractoriness remains a relevant hurdle in the treatment of severe alloimmunized thrombocytopenic patients. Antibodies specific for the human leukocyte antigens (HLA) class I are considered the major immunological cause for PLT transfusion refractoriness. Due to the insufficient availability of HLA-matched PLTs, the development of new technologies is highly desirable to provide an adequate management of thrombocytopenia in immunized patients.
View Article and Find Full Text PDFProteomic study of apheresis platelets made HLA class I deficient for transfusion of refractory patients.
Proteomics Clin Appl
November 2021
Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.
Purpose: Refractoriness can occur after repeated platelet (PLT) transfusions because of alloimmunization to HLA class I antigens on transfused PLTs and generation of anti-HLA antibodies that bind to the foreign PLTs and initiate their destruction. Such refractoriness can be overcome by provision of HLA-matched PLTs from HLA typed donors. However, since the procedure is both expensive and time-consuming, an alternative approach is to deplete PLTs of HLA class I molecules by a brief treatment with citric acid, on ice.
View Article and Find Full Text PDFHLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
Transfusion
April 2021
Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.
Background: Patients can form antibodies to foreign human leukocyte antigen (HLA) Class I antigens after exposure to allogeneic cells. These anti-HLA class I antibodies can bind transfused platelets (PLTs) and mediate their destruction, thus leading to PLT refractoriness. Patients with PLT refractoriness need HLA-matched PLTs, which require expensive HLA typing of donors, antibody analyses of patient sera and/or crossmatching.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!